vs
合众银行（FSBC）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是ARS Pharmaceuticals, Inc.的1.6倍（$45.1M vs $28.1M），合众银行净利率更高（41.3% vs -147.1%，领先188.4%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
FSBC vs SPRY — 直观对比
营收规模更大
FSBC
是对方的1.6倍
$28.1M
净利率更高
FSBC
高出188.4%
-147.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $28.1M |
| 净利润 | $18.6M | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | — | -147.6% |
| 净利率 | 41.3% | -147.1% |
| 营收同比 | — | -67.6% |
| 净利润同比 | 42.0% | -182.8% |
| 每股收益（稀释后） | $0.87 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCSPRY
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $28.1M | ||
| Q3 25 | $41.3M | $32.5M | ||
| Q2 25 | $38.3M | $15.7M | ||
| Q1 25 | $35.3M | $8.0M | ||
| Q4 24 | $35.2M | $86.6M | ||
| Q3 24 | $31.8M | $2.1M | ||
| Q2 24 | $30.7M | $500.0K |
净利润FSBCSPRY
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $-41.3M | ||
| Q3 25 | $16.3M | $-51.2M | ||
| Q2 25 | $14.5M | $-44.9M | ||
| Q1 25 | $13.1M | $-33.9M | ||
| Q4 24 | $13.3M | $49.9M | ||
| Q3 24 | $10.9M | $-19.1M | ||
| Q2 24 | $10.8M | $-12.5M |
营业利润率FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -147.6% | ||
| Q3 25 | 53.8% | -163.7% | ||
| Q2 25 | 52.4% | -302.9% | ||
| Q1 25 | 52.0% | -466.3% | ||
| Q4 24 | 55.1% | 54.5% | ||
| Q3 24 | 48.0% | -1051.6% | ||
| Q2 24 | 49.4% | -3068.0% |
净利率FSBCSPRY
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | -147.1% | ||
| Q3 25 | 39.6% | -157.4% | ||
| Q2 25 | 37.9% | -285.6% | ||
| Q1 25 | 37.1% | -425.7% | ||
| Q4 24 | 37.9% | 57.7% | ||
| Q3 24 | 34.4% | -925.0% | ||
| Q2 24 | 35.2% | -2503.2% |
每股收益（稀释后）FSBCSPRY
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $-0.41 | ||
| Q3 25 | $0.77 | $-0.52 | ||
| Q2 25 | $0.68 | $-0.46 | ||
| Q1 25 | $0.62 | $-0.35 | ||
| Q4 24 | $0.61 | $0.52 | ||
| Q3 24 | $0.52 | $-0.20 | ||
| Q2 24 | $0.51 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $458.5M | $114.3M |
| 总资产 | $5.0B | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资FSBCSPRY
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
总债务FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FSBCSPRY
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $114.3M | ||
| Q3 25 | $431.3M | $147.7M | ||
| Q2 25 | $416.7M | $192.3M | ||
| Q1 25 | $406.5M | $229.0M | ||
| Q4 24 | $396.6M | $256.8M | ||
| Q3 24 | $389.9M | $201.0M | ||
| Q2 24 | $380.5M | $215.2M |
总资产FSBCSPRY
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $327.7M | ||
| Q3 25 | $4.6B | $372.8M | ||
| Q2 25 | $4.4B | $313.5M | ||
| Q1 25 | $4.2B | $327.3M | ||
| Q4 24 | $4.1B | $351.2M | ||
| Q3 24 | $3.9B | $217.6M | ||
| Q2 24 | $3.6B | $222.0M |
负债/权益比FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $-43.5M | ||
| Q3 25 | $18.8M | $-47.0M | ||
| Q2 25 | $17.8M | $-39.6M | ||
| Q1 25 | $15.5M | $-40.7M | ||
| Q4 24 | $51.8M | $42.0M | ||
| Q3 24 | $17.5M | $-14.5M | ||
| Q2 24 | $16.0M | $-7.3M |
自由现金流FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | — | ||
| Q3 25 | $18.6M | $-47.2M | ||
| Q2 25 | $17.5M | $-39.6M | ||
| Q1 25 | $15.4M | $-40.8M | ||
| Q4 24 | $51.2M | $41.7M | ||
| Q3 24 | $17.3M | $-14.6M | ||
| Q2 24 | $15.8M | $-7.3M |
自由现金流率FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | — | ||
| Q3 25 | 45.0% | -145.4% | ||
| Q2 25 | 45.8% | -252.2% | ||
| Q1 25 | 43.5% | -512.1% | ||
| Q4 24 | 145.5% | 48.2% | ||
| Q3 24 | 54.5% | -706.3% | ||
| Q2 24 | 51.6% | -1463.4% |
资本支出强度FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 0.0% | ||
| Q3 25 | 0.5% | 0.6% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.3% | 1.1% | ||
| Q4 24 | 1.8% | 0.3% | ||
| Q3 24 | 0.7% | 6.8% | ||
| Q2 24 | 0.7% | 7.6% |
现金转化率FSBCSPRY
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | 0.84× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
